TY - JOUR
T1 - Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE)
T2 - A Translational, Integrated, and Transdisciplinary Approach
AU - Paquet, Maryse
AU - Cerasuolo, Joshua O.
AU - Thorburn, Victoria
AU - Fridman, Sebastian
AU - Alsubaie, Rasha
AU - Lopes, Renato D.
AU - Cipriano, Lauren E.
AU - Salamone, Paula
AU - Melling, C. W.James
AU - Khan, Ali R.
AU - Sedeño, Lucas
AU - Fang, Jiming
AU - Drangova, Maria
AU - Montero-Odasso, Manuel
AU - Mandzia, Jennifer
AU - Khaw, Alexander V.
AU - Racosta, Juan M.
AU - Paturel, Justin
AU - Samoilov, Lucy
AU - Stirling, Devin
AU - Balint, Brittany
AU - Jaremek, Victoria
AU - Koschinsky, Marlys L.
AU - Boffa, Michael B.
AU - Summers, Kelly
AU - Ibañez, Agustín
AU - Mrkobrada, Marko
AU - Saposnik, Gustavo
AU - Kimpinski, Kurt
AU - Whitehead, Shawn N.
AU - Sposato, Luciano A.
N1 - Funding Information:
Grant support: This study is funded by the Kathleen & Dr Henry Barnett Research Chair in Stroke Research (Western University, London, Ontario, Canada), the Western University Medical and Health Sciences Research Board Seed Research Grant, and the Edward and Alma Saraydar Neurosciences Fund (London Health Sciences Foundation). V. Thorburn is a Lawson Research Fund Scholar. B. Balint is supported by a Boehringer Ingelheim stroke research fellowship. C.W.J. Melling is supported by the Natural Sciences and Engineering Council Discovery Grant (RGPGP-2015-00059). A.R. Khan is supported by grants from the Natural Sciences and Engineering Research Council (NSERC) (RGPIN-2015-06639). M.L. Koschinsky is supported by grants from Canadian Institutes of Health Research (CIHR MOP-# 126076), Heart and Stroke Foundation of Canada (G-13-0003091 and G-17-0018740), NSERC (RGPIN/5006-2015), and Pfizer (W1207819). M.B. Boffa is supported by a grant from the NSERC (RGPIN 05571-2017). A. Ibanez is partially supported by grants from CONICET, CONICYT/FONDECYT Regular (1170010), FONCyT-PICT 2012-0412, FONCyT-PICT 2012-1309, and the INECO Foundation. S.N. Whitehead is supported by NSERC (418489), CIHR (126126), Canadian Foundation for Innovation (CFI 34213), and the Canadian Consortium for Neurodegeneration and Aging (CCNA). L.A. Sposato is supported by the Kathleen & Dr Henry Barnett Research Chair in Stroke Research, the Edward and Alma Saraydar Neurosciences Fund, and the Opportunities Fund of the Academic Health Sciences Center Alternative Funding Plan of the Academic Medical Organization of Southwestern Ontario (AMOSO).
Publisher Copyright:
© 2018 National Stroke Association
PY - 2018/3
Y1 - 2018/3
N2 - Background: It has been hypothesized that ischemic stroke can cause atrial fibrillation. By elucidating the mechanisms of neurogenically mediated paroxysmal atrial fibrillation, novel therapeutic strategies could be developed to prevent atrial fibrillation occurrence and perpetuation after stroke. This could result in fewer recurrent strokes and deaths, a reduction or delay in dementia onset, and in the lessening of the functional, structural, and metabolic consequences of atrial fibrillation on the heart. Methods: The Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE) study is an investigator-driven, translational, integrated, and transdisciplinary initiative. It comprises 3 complementary research streams that focus on atrial fibrillation detected after stroke: experimental, clinical, and epidemiological. The experimental stream will assess pre- and poststroke electrocardiographic, autonomic, anatomic (brain and heart pathology), and inflammatory trajectories in an animal model of selective insular cortex ischemic stroke. The clinical stream will prospectively investigate autonomic, inflammatory, and neurocognitive changes among patients diagnosed with atrial fibrillation detected after stroke by employing comprehensive and validated instruments. The epidemiological stream will focus on the demographics, clinical characteristics, and outcomes of atrial fibrillation detected after stroke at the population level by means of the Ontario Stroke Registry, a prospective clinical database that comprises over 23,000 patients with ischemic stroke. Conclusions: PARADISE is a translational research initiative comprising experimental, clinical, and epidemiological research aimed at characterizing clinical features, the pathophysiology, and outcomes of neurogenic atrial fibrillation detected after stroke.
AB - Background: It has been hypothesized that ischemic stroke can cause atrial fibrillation. By elucidating the mechanisms of neurogenically mediated paroxysmal atrial fibrillation, novel therapeutic strategies could be developed to prevent atrial fibrillation occurrence and perpetuation after stroke. This could result in fewer recurrent strokes and deaths, a reduction or delay in dementia onset, and in the lessening of the functional, structural, and metabolic consequences of atrial fibrillation on the heart. Methods: The Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE) study is an investigator-driven, translational, integrated, and transdisciplinary initiative. It comprises 3 complementary research streams that focus on atrial fibrillation detected after stroke: experimental, clinical, and epidemiological. The experimental stream will assess pre- and poststroke electrocardiographic, autonomic, anatomic (brain and heart pathology), and inflammatory trajectories in an animal model of selective insular cortex ischemic stroke. The clinical stream will prospectively investigate autonomic, inflammatory, and neurocognitive changes among patients diagnosed with atrial fibrillation detected after stroke by employing comprehensive and validated instruments. The epidemiological stream will focus on the demographics, clinical characteristics, and outcomes of atrial fibrillation detected after stroke at the population level by means of the Ontario Stroke Registry, a prospective clinical database that comprises over 23,000 patients with ischemic stroke. Conclusions: PARADISE is a translational research initiative comprising experimental, clinical, and epidemiological research aimed at characterizing clinical features, the pathophysiology, and outcomes of neurogenic atrial fibrillation detected after stroke.
KW - Ischemic stroke
KW - atrial fibrillation
KW - outcome
KW - pathophysiology
KW - prognosis
KW - recurrence
UR - http://www.scopus.com/inward/record.url?scp=85034595349&partnerID=8YFLogxK
U2 - 10.1016/j.jstrokecerebrovasdis.2017.09.038
DO - 10.1016/j.jstrokecerebrovasdis.2017.09.038
M3 - Article
C2 - 29141778
AN - SCOPUS:85034595349
SN - 1052-3057
VL - 27
SP - 606
EP - 619
JO - Journal of Stroke and Cerebrovascular Diseases
JF - Journal of Stroke and Cerebrovascular Diseases
IS - 3
ER -